Patents by Inventor Marion Lanier

Marion Lanier has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9345713
    Abstract: The present invention provides a method of treating acute heart failure by administering a compound of the formula: or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: April 22, 2015
    Date of Patent: May 24, 2016
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Jason W. Brown, Melinda Davis, Anthony Ivetac, Benjamin Jones, Andre A. Kiryanov, Jon Kuehler, Marion Lanier, Joanne Miura, Sean Murphy, Xiaolun Wang
  • Patent number: 9233926
    Abstract: Small molecule compounds and methods for stem cell differentiation are provided herein. An example of a class of compounds that may be used to practice the methods disclosed herein is represented by enantiomerically pure isomers of compounds of Formula I: or a chirally pure stereoisomer, pharmaceutically acceptable salt, or solvate thereof, wherein R1, R2, R3, R4, R5, R5?, R6, R6?, R7, R7? are as described herein.
    Type: Grant
    Filed: March 23, 2012
    Date of Patent: January 12, 2016
    Assignees: Sanford-Burnham Medical Research Institute, Human Biomolecular Research Institute, ChemRegen, Inc.
    Inventors: Mark Mercola, John Cashman, Marion Lanier, Erik Willems, Dennis Schade
  • Publication number: 20150224113
    Abstract: The present invention provides a method of treating acute heart failure by administering a compound of the formula: or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: April 22, 2015
    Publication date: August 13, 2015
    Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Jason W. Brown, Melinda Davis, Anthony Ivetac, Benjamin Jones, Andre A. Kiryanov, Jon Kuehler, Marion Lanier, Joanne Miura, Sean Murphy, Xiaolun Wang
  • Patent number: 9040522
    Abstract: The present invention provides compounds of the formula: which are useful as inhibitors of PHD and pharmaceutical compositions thereof.
    Type: Grant
    Filed: March 26, 2014
    Date of Patent: May 26, 2015
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Jason W. Brown, Melinda Davis, Anthony Ivetac, Benjamin Jones, Andre A. Kiryanov, Jon Kuehler, Marion Lanier, Joanne Miura, Sean Murphy, Xiaolun Wang
  • Patent number: 9023340
    Abstract: Methods and small molecule compounds for stem cell differentiation and treatment of animals with diseases are provided. One example of a class of compounds that may be used is represented by the compound of Formula I and II: or a pharmaceutically acceptable salt or solvate thereof, wherein A, X, Q, R1, R2, R3, R4 are as described herein.
    Type: Grant
    Filed: July 2, 2012
    Date of Patent: May 5, 2015
    Assignee: ChemRegen, Inc.
    Inventors: John Cashman, Marion Lanier, Mark Mercola, Dennis Schade, Erik Willems
  • Publication number: 20140296200
    Abstract: The present invention provides compounds of the formula: which are useful as inhibitors of PHD, pharmaceutical compositions thereof, methods for treatment of conditions associated with HIF, processes for making the compounds and intermediates thereof.
    Type: Application
    Filed: March 26, 2014
    Publication date: October 2, 2014
    Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Jason W. Brown, Melinda Davis, Anthony Ivetac, Benjamin Jones, Andre A. Kiryanov, Jon Kuehler, Marion Lanier, Joanne Miura, Sean Murphy, Xiaolun Wang
  • Publication number: 20130177535
    Abstract: Methods and small molecule compounds for stem cell differentiation and treatment of animals with diseases are provided. One example of a class of compounds that may be used is represented by the compound of Formula I and II: or a pharmaceutically acceptable salt or solvate thereof, wherein A, X, Q, R1, R2, R3, R4 are as described herein.
    Type: Application
    Filed: July 2, 2012
    Publication date: July 11, 2013
    Inventors: John Cashman, Marion Lanier, Mark Mercola, Dennis Schade, Erik Willems
  • Publication number: 20130157947
    Abstract: Small molecule compounds and methods for stem cell differentiation are provided herein. An example of a class of compounds that may be used to practice the methods disclosed herein is represented by enantiomerically pure isomers of compounds of Formula I: or a chirally pure stereoisomer, pharmaceutically acceptable salt, or solvate thereof, wherein R1, R2, R3, R4, R5, R5?, R6, R6?, R7, R7? are as described herein.
    Type: Application
    Filed: March 23, 2012
    Publication date: June 20, 2013
    Inventors: MARK MERCOLA, John Cashman, Marion Lanier, Erik Willems, Dennis Schade
  • Publication number: 20110281356
    Abstract: Methods and small molecule compounds for stem cell differentiation are provided. One example of a class of compounds that may be used is represented by the compound of Formula I: or a pharmaceutically acceptable salt or solvate thereof, wherein R1, R2, R3, R4, R5, R5?, R6, R6?, R7, R7? are as described herein.
    Type: Application
    Filed: May 13, 2011
    Publication date: November 17, 2011
    Applicants: Human BioMolecular Research Institute, Sanford-Burnham Medical Research Institute
    Inventors: Mark Mercola, John Cashman, Marion Lanier, Erik Willems
  • Patent number: 7879862
    Abstract: CRF receptor antagonists are disclosed which may have utility in the treatment of a variety of disorders, including the treatment of disorders manifesting hypersecretion of CRF in mammals. The CRF receptor antagonists of this invention have the following structure: (I); and pharmaceutically acceptable salts, esters, solvates, stereoisomers and prodrugs thereof, wherein R1, R2a, R2b, Y, Het, n, o, R6, Ar and R7 are as defined herein. Compositions containing a CRF receptor antagonist in combination with a pharmaceutically acceptable carrier are also disclosed, as well as methods for use of the same.
    Type: Grant
    Filed: October 19, 2005
    Date of Patent: February 1, 2011
    Assignee: SmithKline Beecham (Cork) Limited
    Inventors: Marion Lanier, John Edward Tellew, John P. Williams
  • Publication number: 20100234341
    Abstract: Compounds of formula (I) including pharmaceutically acceptable salts, esters, solvates and stereoisomers thereof, R1, R2 and R3 are as defined herein. Pharmaceutical compositions containing a compound of structure (I), as well as methods relating to the use thereof, are also disclosed.
    Type: Application
    Filed: December 4, 2007
    Publication date: September 16, 2010
    Inventors: Marion Lanier, Deborah Slee, Emily Lin, Zhiyong Robert Luo, Yongsheng Chen, Manisha Moorjani, Binh G. Vong, John Tellew
  • Patent number: 7652035
    Abstract: CRF receptor antagonists are disclosed which may have utility in the treatment of a variety of disorders, including the treatment of disorders manifesting hypersecretion of CRF in mammals, such as stroke. The CRF receptor antagonists of this invention have the following structure: and pharmaceutically acceptable salts, esters, solvates, stereoisomers and prodrugs thereof, wherein R1, R2, n, R5, Ar, and Het are as defined herein. Compositions containing a CRF receptor antagonists in combination with a pharmaceutically acceptable carrier are also disclosed, as well as methods for use of the same.
    Type: Grant
    Filed: October 17, 2005
    Date of Patent: January 26, 2010
    Assignees: Neurocrine Bioscience, Inc., SB Cork
    Inventors: Marion Lanier, Manisha Moorjani, John Edward Tellew, John P. Williams
  • Publication number: 20080275064
    Abstract: Compounds of formula (I), including pharmaceutically acceptable salts, esters, solvates and stereoisomers thereof, R1, R2 and R3 are as defined herein. Pharmaceutical compositions containing a compound of structure (I), as well as methods relating to the use thereof as antagonists of adenosine receptors, in particular antagonists of the A2A adenosine receptor subtype.
    Type: Application
    Filed: April 11, 2006
    Publication date: November 6, 2008
    Inventors: Deborah Slee, Marion Lanier, Binh G. Vong, Yongsheng Chen, Xiaohu Zhang, Emily Lin, Manisha Moorjani, Julio Cesar Castro Palomino Laria
  • Publication number: 20080194589
    Abstract: CRF receptor antagonists are disclosed which may have utility in the treatment of a variety of disorders, including the treatment of disorders manifesting hypersecretion of CRF in mammals. The CRF receptor antagonists of this invention have the following structure: (I); and pharmaceutically acceptable salts, esters, solvates, stereoisomers and prodrugs thereof, wherein R1, R2a, R2b, Y, Het, n, o, R6, Ar and R7 are as defined herein. Compositions containing a CRF receptor antagonist in combination with a pharmaceutically acceptable carrier are also disclosed, as well as methods for use of the same.
    Type: Application
    Filed: October 19, 2005
    Publication date: August 14, 2008
    Applicant: NEUROCRINE BIOSCIENCES, INC.
    Inventors: Marion Lanier, Zhiyong Luo, Manisha Moorjani, John Edward Tellew, John P. Williams, Xiaohu Zhang
  • Publication number: 20080064719
    Abstract: CRF receptor antagonists are disclosed which may have utility in the treatment of a variety of disorders, including the treatment of disorders manifesting hypersecretion of CRF in mammals, such as stroke. The CRF receptor antagonists of this invention have the following structure: and pharmaceutically acceptable salts, esters, solvates, stereoisomers and prodrugs thereof, wherein R1, R2, n, R5, Ar, and Het are as defined herein. Compositions containing a CRF receptor antagonists in combination with a pharmaceutically acceptable carrier are also disclosed, as well as methods for use of the same.
    Type: Application
    Filed: October 17, 2005
    Publication date: March 13, 2008
    Inventors: Marion Lanier, Manisha Moorjani, John Tellew, John Williams